Antibody Drug Conjugates Market Trends Report | Growth Forecasts to 2030
[Research Report] The antibody drug conjugates market size is projected to reach US$ 29,600.98 million by 2030 from US$ 7,793.43 million in 2022; the market is estimated to record a CAGR of 18.2% from 2022 to 2030.
Market Insights and Analyst View:
Antibody-drug conjugates or ADCs are targeted medicines that help deliver chemotherapy agents to cancer cells. A chemotherapy substance is linked to a monoclonal antibody to facilitate their binding to a specific target expressed on cancer cell surfaces. Due to their accuracy and efficiency in killing cancer cells, ADCs have become one of the major hotspots for the R&D of anticancer drugs. Growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs drive the market growth. On the other hand, the high cost of ADC development and commercialization hinders the antibody drug conjugates market growth.
Growth Drivers:
Rising Incidence of Cancer Cases Propels Antibody Drug Conjugates Market Growth
The rising incidence of cancer is primarily bolstering the demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. The US, China, and India were among the countries with the highest number of cancer cases. GLOBOCAN also estimates that the cancer cases in India would reach ~2.08 million by 2040, representing a rise of 57.5% from 2020. As per the World Health Organization (WHO) data published in February 2022, ~10 million people in the world have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. A list of common cancer cases reported worldwide in 2020 is provided below.
New Cancer Cases Worldwide, in 2020
Sr. No. | Cancer Type | Cases (Million) |
1 | Stomach | 1.09 |
2 | Skin (Non-Melanoma) | 1.2 |
3 | Prostate | 1.41 |
4 | Colon and Rectum | 1.93 |
5 | Lung | 2.21 |
6 | Breast | 2.26 |
Source: World Health Organization, February 2020
Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and those who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnoses in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Antibody Drug Conjugates Market: Strategic Insights
Market Size Value in US$ 7,793.43 million in 2022 Market Size Value by US$ 29,600.98 million by 2030 Growth rate CAGR of 18.2% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Antibody Drug Conjugates Market: Strategic Insights
| Market Size Value in | US$ 7,793.43 million in 2022 |
| Market Size Value by | US$ 29,600.98 million by 2030 |
| Growth rate | CAGR of 18.2% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The “Antibody Drug Conjugates Market” is segmented on the basis of technology, application, and distributional channel. By technology, the antibody drug conjugates market is bifurcated into cleavable and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022–2030. Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share and is estimated to register the fastest CAGR during 2022–2030. The antibody drug conjugates market, by distribution channel, is segmented into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment held the largest market share, and the segment is estimated to record the fastest CAGR during 2022–2030.
Segmental Analysis:
By technology, the antibody–drug conjugates market is bifurcated into cleavable and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022–2030. Non-cleavable linkers are further classified into thioether or maleimidocaproyl (MC) group linkers. Unlike cleavable linkers, non-cleavable ADCs are more dependent on the biology of target cells. ADCs developed using non-cleavable linker technology show decreased payload potency. This technology increases plasma stability and improves the therapeutic index of cancer treatment. Many studies have shown that non-cleavable linker technology used for the in vivo development of ADCs performs better than their cleavable counterparts. Also, non-cleavable linker technology provides a potentially larger therapeutic window than cleavable linkers, thus allowing ADC payload derivatives to kill target cells more effectively.
Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and it is further estimated to register the fastest CAGR of 18.6% during 2022–2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.
The antibody drug conjugates market, by distribution channel, is segmented into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment held the largest market share, and it is estimated to record the fastest CAGR of 18.5% during 2022–2030. Hospital pharmacies are specialized pharmacies integrated into healthcare centers such as hospitals, clinics, and drug rehabilitation centers. Hospital pharmacies widely distribute prescribed drugs. ADCs are prescribed as advanced therapies for treating cancer, and thus, their dispensation requires more attention and care. As a result, ADCs are widely distributed through hospital pharmacies. In addition, hospital pharmacies have capacities to support the storage of extensive stocks.
Reimbursement on drugs purchased under healthcare plans is the primary benefit conferred by hospital pharmacies. They also have specialized stock-keeping and storage facilities even for investigational medications (which are being studied but have not yet been approved), which other community settings do not have. On the other hand, hospital pharmacies are not retail establishments and do not provide medications for non-hospitalized patients. They can purchase medicines directly from a manufacturer or supplier, eliminating a long distribution network.
Regional Analysis - Antibody Drug Conjugates Market:
Based on geography, the antibody drug conjugates market is segmented into five key regions: North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the antibody drug conjugates market. Asia Pacific is expected to register the highest CAGR in the global antibody drug conjugates market during 2022–2030.
North America holds the largest share of the antibody drug conjugates market. The market in this region is split into the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs; rising product approvals; growing awareness about ADCs; and a surging number of mergers, collaborations, and partnerships among market players. In addition, the significantly growing incidence of cancer is propelling the demand for ADCs. The US is the largest contributor to the antibody drug conjugates market in North America and the world. The highest number of ADCs are approved in the US. By January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In addition, several ADCs are in the pipeline in the US. ADCs have been developed with strategies such as advanced conjugate technologies, more potent payloads, targeting novel antigens, and novel linkers. According to the FDA’s data published in May 2021, 113 clinical trials were underway for 77 novel ADCs that targeted over 40 different targets.
The Asia Pacific antibody drug conjugates (ADCs) market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the ADCs market in this region is widely driven by collaborations between companies, rising incidence of cancer, and an increasing number of clinical trials. China is home to various innovators of ADCs that are exponentially contributing to the market growth. Players such as RemeGen Co., Ltd.; Zhejiang Medicine Co., Ltd.; and Jiangsu Hengrui Pharmaceuticals Company Ltd. are among the leaders in the ADCs market in the country. These companies are involved in developing ADCs to treat breast, gastric, and urothelial cancers. Companies have various products in the pipeline that are ready for launch in the market after the completion of clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin-targeting (MSLN-targeting) antibody-drug conjugate (ADC) or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has a Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different indications; the first combination is in phase III for the evaluation of its efficacy in treating urothelial cancer, while the second is in phase II for the examination of its capability to treat muscle-invasive bladder and gastric cancer.
Antibody Drug Conjugates Market Report Scope
Industry Developments and Future Opportunities – Antibody Drug Conjugates Market:
Various initiatives taken by leading players operating in the antibody drug conjugates market are listed below:
- In June 2023, Innovent Biologics, Inc. and RemeGen Co., Ltd. entered into a clinical trial collaboration and supply agreement for the combination therapies of TYVYT (sintilimab injection) with RC88 [a novel mesothelin (MSLN)-targeting ADC] or RC108 [a novel c-Met-targeting ADC] as potential treatment options for advanced solid tumors in China. Under the agreement, Innovent would provide clinical drug supplies of TYVYT (sintilimab injection) during the clinical trial collaboration. RemeGen would conduct Phase 1/2a clinical trials to study the safety and antitumor activity of the combination therapy of TYVYT (sintilimab injection) with RC88 or RC108 in Chinese patients with advanced solid tumors.
- In July 2022, AstraZeneca signed a new global development and commercialization agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo’s proprietary ADC directed toward trophoblast cell-surface antigen 2 (TROP2), a potential new medicine for the treatment of multiple tumor types. DS-1062 is currently in the development phase for its activity against multiple tumors that commonly express TROP2, a cell-surface glycoprotein. TROP2 is overexpressed in almost all non-small cell lung cancers1 and breast cancers—2,3 tumor types, which have been a strategic focus for AstraZeneca for a long. This collaboration indicates AstraZeneca’s strategy to invest in ADC through the successful existing collaboration with Daiichi Sankyo.
- In January 2022, Gilead Sciences, Inc. entered into two clinical trial collaborations and supply agreements with Merck (MSD outside of Canada and the US) to evaluate the combination of Gilead’s Trodelvy (sacituzumab govitecan-hziy) ADC targeting TROP-2 and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). As part of this collaboration, Merck is expected to sponsor a global Phase 3 clinical trial of Trodelvy combined with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC.
Competitive Landscape and Key Companies - Antibody Drug Conjugates Market:
ADC Therapeutics SA; Pfizer Inc; F. Hoffmann-La Roche Ltd; ImmunoGen, Inc; GSK Plc; Gilead Sciences Inc; AstraZeneca Plc; Astellas Pharma Inc; RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd. are the prominent antibody drug conjugates market companies. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Technology, Application, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR during 2022–2030.
Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker.
The antibody drug conjugates market majorly consists of the players such as ADC Therapeutics, Gilead Sciences, Inc, AstraZeneca, RemeGen, Roche, GSK, and Takeda, ImmunoGen, Astellas, Pfizer.
The growth of the market is attributed to the growing strategic partnerships to develop of antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. Whereas high cost of ADCs development and commercialization is hindering the market growth.
The antibody drug conjugates (ADCs) market is analyzed based on North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. North America is expected to hold significant market share in 2022. North America is analyzed based on the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Antibody Drug Conjugates Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
4.3 List of Vendors
4.3.1 List of Vendors in the Value Chain
5. Antibody Drug Conjugates Market - Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
5.1.2 Rising Incidences of Cancer Cases
5.1.3 Increasing FDA Approvals for ADCs
5.2 Market Restraints
5.2.1 High Cost of ADCs Development and Commercialization
5.3 Market Opportunities
5.3.1 Increasing Investments to Develop ADCs
5.4 Market Trends
5.4.1 Escalating Pipeline of ADCs
5.5 Impact Analysis:
6. Antibody Drug Conjugates Market - Global Market Analysis
6.1 Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
7. Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Technology
7.1 Overview
7.2 Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
7.3 Cleavable Linker
7.3.1 Overview
7.3.2 Cleavable Linker: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Non-cleavable Linker
7.4.1 Overview
7.4.2 Non-cleavable Linker: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8. Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Blood Cancer
8.3.1 Overview
8.3.2 Blood Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Breast Cancer
8.4.1 Overview
8.4.2 Breast Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Ovarian Cancer
8.5.1 Overview
8.5.2 Ovarian Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Urothelial Cancer
8.6.1 Overview
8.6.2 Urothelial Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9. Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Distribution Channel
9.1 Overview
9.2 Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
10. Antibody Drug Conjugates Market - Regional Analysis
10.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Antibody Drug Conjugates Market, by Technology
10.1.4 North America: Antibody Drug Conjugates Market, by Application
10.1.5 North America: Antibody Drug Conjugates Market, by Distribution Channel
10.1.6 North America: Antibody Drug Conjugates Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Antibody Drug Conjugates Market, by Technology
10.1.6.1.4 US: Antibody Drug Conjugates Market, by Application
10.1.6.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Antibody Drug Conjugates Market, by Technology
10.1.6.2.4 Canada: Antibody Drug Conjugates Market, by Application
10.1.6.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
10.1.6.3.4 Mexico: Antibody Drug Conjugates Market, by Application
10.1.6.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel
10.2 Europe Antibody Drug Conjugates Market, Revenue and Forecast To 2030
10.2.1 Overview
10.2.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Antibody Drug Conjugates Market, by Technology
10.2.4 Europe: Antibody Drug Conjugates Market, by Application
10.2.5 Europe: Antibody Drug Conjugates Market, by Distribution Channel
10.2.6 Europe: Antibody Drug Conjugates Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Antibody Drug Conjugates Market, by Technology
10.2.6.1.4 UK: Antibody Drug Conjugates Market, by Application
10.2.6.1.5 UK: Antibody Drug Conjugates Market, by Distribution Channel
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Antibody Drug Conjugates Market, by Technology
10.2.6.2.4 Germany: Antibody Drug Conjugates Market, by Application
10.2.6.2.5 Germany: Antibody Drug Conjugates Market, by Distribution Channel
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Antibody Drug Conjugates Market, by Technology
10.2.6.3.4 France: Antibody Drug Conjugates Market, by Application
10.2.6.3.5 France: Antibody Drug Conjugates Market, by Distribution Channel
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Antibody Drug Conjugates Market, by Technology
10.2.6.4.4 Italy: Antibody Drug Conjugates Market, by Application
10.2.6.4.5 Italy: Antibody Drug Conjugates Market, by Distribution Channel
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Antibody Drug Conjugates Market, by Technology
10.2.6.5.4 Spain: Antibody Drug Conjugates Market, by Application
10.2.6.5.5 Spain: Antibody Drug Conjugates Market, by Distribution Channel
10.2.6.6 Rest of Europe
10.2.6.6.1 Overview
10.2.6.6.2 Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.3 Rest of Europe: Antibody Drug Conjugates Market, by Technology
10.2.6.6.4 Rest of Europe: Antibody Drug Conjugates Market, by Application
10.2.6.6.5 Rest of Europe: Antibody Drug Conjugates Market, by Distribution Channel
10.3 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
10.3.1 Overview
10.3.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Antibody Drug Conjugates Market, by Technology
10.3.4 Asia Pacific: Antibody Drug Conjugates Market, by Application
10.3.5 Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
10.3.6 Asia Pacific: Antibody Drug Conjugates Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Antibody Drug Conjugates Market, by Technology
10.3.6.1.4 China: Antibody Drug Conjugates Market, by Application
10.3.6.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Antibody Drug Conjugates Market, by Technology
10.3.6.2.4 Japan: Antibody Drug Conjugates Market, by Application
10.3.6.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Antibody Drug Conjugates Market, by Technology
10.3.6.3.4 India: Antibody Drug Conjugates Market, by Application
10.3.6.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
10.3.6.4 South Korea
10.3.6.4.1 Overview
10.3.6.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
10.3.6.4.4 South Korea: Antibody Drug Conjugates Market, by Application
10.3.6.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
10.3.6.5 Australia
10.3.6.5.1 Overview
10.3.6.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 Australia: Antibody Drug Conjugates Market, by Technology
10.3.6.5.4 Australia: Antibody Drug Conjugates Market, by Application
10.3.6.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
10.3.6.6 Rest of Asia Pacific
10.3.6.6.1 Overview
10.3.6.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
10.3.6.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
10.3.6.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
10.4 Middle East & Africa Antibody Drug Conjugates Market, Revenue and Forecast To 2030
10.4.1 Overview
10.4.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Antibody Drug Conjugates Market, by Technology
10.4.4 Middle East & Africa: Antibody Drug Conjugates Market, by Application
10.4.5 Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
10.4.6 Middle East & Africa: Antibody Drug Conjugates Market, by Country
10.4.6.1 Saudi Arabia
10.4.6.1.1 Overview
10.4.6.1.2 Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.1.3 Saudi Arabia: Antibody Drug Conjugates Market, by Technology
10.4.6.1.4 Saudi Arabia: Antibody Drug Conjugates Market, by Application
10.4.6.1.5 Saudi Arabia: Antibody Drug Conjugates Market, by Distribution Channel
10.4.6.2 UAE
10.4.6.2.1 Overview
10.4.6.2.2 UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.2.3 UAE: Antibody Drug Conjugates Market, by Technology
10.4.6.2.4 UAE: Antibody Drug Conjugates Market, by Application
10.4.6.2.5 UAE: Antibody Drug Conjugates Market, by Distribution Channel
10.4.6.3 South Africa
10.4.6.3.1 Overview
10.4.6.3.2 South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.3.3 South Africa: Antibody Drug Conjugates Market, by Technology
10.4.6.3.4 South Africa: Antibody Drug Conjugates Market, by Application
10.4.6.3.5 South Africa: Antibody Drug Conjugates Market, by Distribution Channel
10.4.6.4 Rest of Middle East & Africa
10.4.6.4.1 Overview
10.4.6.4.2 Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.4.3 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Technology
10.4.6.4.4 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Application
10.4.6.4.5 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
10.5 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
10.5.1 Overview
10.5.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Antibody Drug Conjugates Market, by Technology
10.5.4 South & Central America: Antibody Drug Conjugates Market, by Application
10.5.5 South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
10.5.6 South & Central America: Antibody Drug Conjugates Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
10.5.6.1.4 Brazil: Antibody Drug Conjugates Market, by Application
10.5.6.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Antibody Drug Conjugates Market, by Technology
10.5.6.2.4 Argentina: Antibody Drug Conjugates Market, by Application
10.5.6.2.5 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
10.5.6.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
10.5.6.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
11. Antibody Drug Conjugates Market–Industry Landscape
11.1 Overview
11.2 Organic Growth Strategies
11.2.1 Overview
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Companies’ Manufacturing Capacities and Capabilities
12. Company Profiles
12.1 ADC Therapeutics SA
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Pfizer Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ImmunoGen, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Gilead Sciences Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AstraZeneca Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 RemeGen Co Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Takeda Pharmaceutical Co Ltd
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
List of Tables
Table 1. Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. New Cancer Cases Worldwide, in 2020
Table 4. List of FDA-Approved ADCs
Table 5. North America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 6. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 7. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 8. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 9. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 10. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 11. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 12. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 13. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 14. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 15. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 16. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 17. Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 18. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 19. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 20. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 21. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 22. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 23. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 24. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 25. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 26. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 27. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 28. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 29. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 30. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 31. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 32. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 34. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 35. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 36. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 37. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 38. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 39. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 40. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 41. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 42. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 43. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 44. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 45. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 46. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 47. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 48. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 49. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 50. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 51. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 52. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 53. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 54. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 55. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 56. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 57. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 58. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 59. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 60. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 61. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 62. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 63. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 64. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 65. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 66. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 67. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 68. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 69. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 70. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 71. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 72. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 73. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 74. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 75. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Application
Table 76. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) – Distribution Channel
Table 77. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 78. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 79. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 80. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 81. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 82. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 83. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 84. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 85. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 86. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 87. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 88. Glossary of Terms, Antibody Drug Conjugates Market
List of Figures
Figure 1. Antibody Drug Conjugates Market Segmentation, By Region
Figure 2. Key Insights
Figure 3. Global - PEST Analysis
Figure 4. Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
Figure 7. Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 8. Cleavable Linker: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Non-Cleavable Linker: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 11. Blood Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Breast Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Ovarian Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Urothelial Cancer: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 17. Hospital Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Retail Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Online Pharmacies: Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 21. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 23. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 27. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Europe: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 29. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 36. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 38. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 45. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 46. Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 47. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 49. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 51. Antibody Drug Conjugates Market, 2022 ($Mn)
Figure 52. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 54. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 56. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
The List of Companies - Antibody Drug Conjugates Market
- ADC Therapeutics SA
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- ImmunoGen, Inc.
- GSK Plc
- Gilead Sciences Inc.
- AstraZeneca Plc
- Astellas Pharma Inc.
- RemeGen Co Ltd
- Takeda Pharmaceutical Co Ltd
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For